Potential Operations

  • Molecular diagnostics
  • Medical device
  • Biotechnology tools
  • Bioanalytical services
  • Early-stage therapeutics
  • Stem cell companies

Current clients

Join E-mail List

Enter your email unsubscribe
The Bioscience Laboratories enables companies to initiate their scientific R&D programs without establishing their own laboratory space, saving them time and money and helping them to achieve their goals.

News about companies in the Bioscience Labs

  • Aelan Cell Technologies announces development of biomarker for Alzheimers' disease. An early human study of the novel epigenetic biomarker indicated serological tests using it with other proprietary components developed by Aelan's researchers could potentially aid in diagnosis of Alzheimer's.

    Click here to read more (July 6, 2016)

  • Taxa Biotechnologies introduces its first fragrant moss.

    The moss that has patchouli fragrance was developed in a collaboration with the University of Copenhagen to the public for the first time. (June 1, 2016)

  • Taxa Biotechnologies (previously Glowing Plant), the first biotech investment of Y Combinator, launches crowdfunding offering via Wefunder Portal LLC

    Click here to read more. (May 16, 2016)

  • Seeking a fresh start in gene therapy, Avalanche, a former BSL company, merges with Annapurna

    Click here to read the article. (Feb 1, 2016)

  • PuraCath Medical, a former BSL company, receives 510(k) clearance for the FireFly™ Peritoneal Dialysis Connector Disinfecting System

    Click here to read the article. (Jan 26, 2016)

  • Aelan collaborates with Gladstone Institutes to conduct comparative study on stem cells

    Click here to read the article. (Sept 29, 2015)

  • Adynxx Reports Positive Results for Phase 2b Study of AYX1,

    Click here to read the article. (Aug 11, 2015)

  • A second startup initially launching operations at the Bioscience Laboratories successfully completes NASDAQ IPO. Global Blood Therapeutics raises $120 million.

    Click here to read the article. (August 12, 2015)

  • Nuclea Biotechnolgies, Inc., launches strategic partnership with Aelan Cell Technologies for development and commercialization of biomarkers and diagnostics.

    Click here to read the article. (June 30, 2015)

  • Tempo Bioscience's biosensors for live cell cytotoxicity assays featured by Genetic Engineering and Biotechnology News.

    Click here to read the article. (June 1, 2015)

  • Cambrian Genomics featured in front page story on SF Chronicle.

    Click here to read the article. (Jan. 3, 2015)

  • Former Bioscience Laboratories company Avalanche Biotechnologies ($AAVL) pulled off a $102 million Wall Street debut.

    Avalanche plans to fund a pipeline of gene therapies for ocular diseases. Click here to read the article. (July 31, 2014)

  • Tempo Bioscience's Human Cell Models featured in Genetic, Engineering, and Biotechnology News

    Click here to read the article. (June 1, 2014)

  • Tempo Bioscience Launches Human Cellular And Biosensor Products

    Click here to read the article. (March 26, 2014)

  • MandalMed scientists and collaborators one step closer to functioning human artificial testicle for reproductive toxicology

    Meenakshi Gaur, Ph.D., Director of Cell and Molecular Biology at MandalMed, is the first author of presentation at the annual meeting of the American Urological Association in Orlando, FL this week. Click here to read the press release. (May 21, 2014)

  • Glowing Plants to Light Your Home? Here They Come!

    The WSJ's Deborah Kan speaks to Glowing Plant's CEO Antony Evans on the DNA sequencing tech that makes this happen and when we'll see them in stores. Click here to watch the video. (May 14, 2014)

  • Avalanche Biotechnologies and Regeneron Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. Click here to read the press release. (May 5, 2014)

  • Avalanche Biotechnologies Secures $55 Million in Series B Financing

    Proceeds will further strengthen Avalanche's Proprietary BioFactory™ Platform and advance clinical program in wet age-related macular degeneration. Click here to read the press release. (April 22, 2014)

  • Adynxx's lead product candidate, AYX1, was featured in the February issue of PAIN

    "Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury." Click here to read the abstract. (February 1, 2014)

  • Avalanche Raises Additional Funding in Follow-On Financing

    Avalanche announces the completion of additional financing in a round consisting of both new and existing investors. Click here to read more. (November 22, 2013)

  • Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1

    Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of AYX1 in Prevention of Pain Following Total Knee Replacement Click here to read more. (September 5, 2013)

  • MandalMed announces the receipt of Phase I NIH SBIR award

    entitled "Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction" from the National Heart Blood and Lung Institute (September 4, 2013)

  • The winner of the 2013 SXSW V2V competition in the Innovative World Technologies category is Glowing Plant.

    Click here to view the video. (August 14, 2013)

  • AYX1 Injection Designated as a Fast Track Development Program for Prevention of Chronic Pain

    Click here to view the Adynxx press release. (July 17, 2013)

  • SF Business Times article features Bioscience Laboratories Incubator Brewing of Biotech Companies

    Click here to view the article from the SF Business Times. (March 1, 2013)

  • Cubist Announces Exclusive Option to Acquire Adynxx

    Click here to view the article from Xconomy. (February 25, 2013)

  • Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain.

    Study to evaluate safety and tolerability of therapeutic designed to prevent post-operative pain. Read about the study on the Adynxx website. (August 2012)

  • Third Rock Ventures Launches Global Blood Therapeutics with $40.7 Million to Revolutionize the Treatment of Chronic Blood-Based Diseases.

    Read more here. (June 2012)

  • Artificial testis to be developed through SBIR awarded to Drs. Constance John and Paul Turek of MandalMed.

    Read the full story in the NIEHS newsletter. (April 2012)

  • Universal Biomining awarded an STTR grant from the National Aeronautics and Space Administration (NASA) entitled, "Biomining of regolith simulants for biological in situ resource utilization."

    The goal of the project is to investigate the utilization of terrestrial extremophile organisms and novel bioreactor designs for resource extraction on lunar and martian regoliths. In-Situ Resource Utilization (ISRU), or the procurement of materials in space, is be considered necessary for significant space colonization. UBM is partnered with the Search for Extraterrestrial Intelligence (SETI) Institute for this project. (February 2012).

  • Avalanche Biotechnologies launches clinical trial of treatment for wet age-related macular degeneration, a leading cause of blindness.

    Click here to view the article from the SF Business Times. (January 2012)